坦螺旋霉素 T6290

Product Introduction
Bioactivity


英文名: Tanespimycin

描述: Tanespimycin (KOS 953) 是一种 Hsp90 抑制剂，可选择性抑制 BT474 肿瘤细胞 Hsp90，IC50为 5 nM。它消耗细胞内 STK38/NDR1，并降低 STK38 激酶活性，还能下调stk38基因表达。

细胞实验: Cells were seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μl for 24 h before the addition of increasing concentrations of 17-AAG that was incubated for 5 days. Viable cell number was determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells was subtracted. Percentage of viable cells ? (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 was defined as the concentration that gave rise to 50% viable cell number [1].

激酶实验: Purified native Hsp90 protein or cell lysates in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) were incubated with or without 17-AAG for 30 min at 4 °C, and then incubated with biotin-GM linked to streptavidin magnetic beads for 1 h at 4 °C. Tubes were placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads were washed three times in lysis buffer and heated for 5 min at 95 °C in SDS–PAGE sample buffer. Samples were analyzed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots were quantified, and the percentage inhibition of binding of Hsp90 to the biotin-GM was calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding. For in vitro reconstitution, 5 μM of purified Hsp90 was combined with 1 μM each of Hsp70, Hsp40, p23, and Hop purified proteins [1].

动物实验: B10.BR mice were inoculated with 5×10^5 lymphoma cells through intraperitoneal injection. Seven days following tumor implantation, the mice were I.P. injected with 17-AAG or vehicle (10% DMSO + 40% Cremophor EL: Ethanol (3:1) (v/v) + 50 % PBS) every other day for three weeks. At the cessation of treatment, mice were monitored up to 80 days post tumor cell injection. To determine the effects of 17-AAG on lymphoma initiation in vivo, secondary B10.BR recipient mice were implanted by intraperitoneal injection of 1×10^5 lymphoma cells from the spleens of first-round mice that had been treated with 17-AAG or vehicle. These mice were followed up to 160 days post tumor cell injection to monitor differences in tumor initiation between the mice [4].

体外活性: Hsp90 derived from tumour cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells. In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity [1]. 17-AAG caused the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells [2]. Combined 17-AAG and Trastuzumab treatment of ErbB2-overexpressing breast cancer cell lines leads to enhanced ubiquitinylation, downregulation from the cell surface and lysosomal degradation of ErbB2 [3].

体内活性: At non-toxic doses, 17-AAG caused a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. This decline was rapid, with a 97% loss of HER2 and an 80% loss of AR expression at 4 h [2]. In contrast, spleens from mice which had received 17-AAG (5 to 40 mg/kg) were dramatically smaller, with less infiltrating lymphoma cells in the spleen, and a lower metastatic spread into other organs, as compared to the vehicle-treated control. In addition, 17-AAG treated mice survived significantly longer compared to mice which had received vehicle alone [4].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 58.6 mg/mL (100 mM)


关键字: tumor | stk38 | Inhibitor | KOS953 | cancer | prostate | HSP | Heat shock proteins | Mitophagy | NSC-330507 | Mitochondrial Autophagy | Tanespimycin | Apoptosis | CP127374 | inhibit | Autophagy | CP-127374 | HER2 | KOS-953 | A549 | NSC330507 | Bacterial | Antibiotic

相关产品: Sulfasalazine | Quercetin Dihydrate | Levistolide A | Ethoxysanguinarine | Entinostat | INH6 | Benzbromarone | CDKI-73 | LCS3 | Angiotensin II human

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | Hematonosis Compound Library | Microbial Natural Product Library

坦螺旋霉素 T6290信息由TargetMol中国为您提供，如您想了解更多关于坦螺旋霉素 T6290报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途